Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Net Cash Flow (2016 - 2025)

vTv Therapeutics' Net Cash Flow history spans 12 years, with the latest figure at -$9.6 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 98.38% year-over-year to -$9.6 million; the TTM value through Dec 2025 reached $52.2 million, up 91.16%, while the annual FY2025 figure was $52.2 million, 91.16% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$9.6 million at vTv Therapeutics, down from $72.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $72.6 million in Q3 2025 and bottomed at -$9.6 million in Q4 2025.
  • The 5-year median for Net Cash Flow is -$2.9 million (2022), against an average of $4.2 million.
  • The largest annual shift saw Net Cash Flow tumbled 499.42% in 2024 before it surged 1935.2% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$6.2 million in 2021, then soared by 47.76% to -$3.2 million in 2022, then skyrocketed by 137.6% to $1.2 million in 2023, then crashed by 499.42% to -$4.8 million in 2024, then crashed by 98.38% to -$9.6 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Net Cash Flow are -$9.6 million (Q4 2025), $72.6 million (Q3 2025), and -$5.1 million (Q2 2025).